BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Catani JPP, Medrano RFV, Hunger A, Del Valle P, Adjemian S, Zanatta DB, Kroemer G, Costanzi-Strauss E, Strauss BE. Intratumoral Immunization by p19Arf and Interferon-β Gene Transfer in a Heterotopic Mouse Model of Lung Carcinoma. Transl Oncol 2016;9:565-74. [PMID: 27916291 DOI: 10.1016/j.tranon.2016.09.011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Medrano RFV, Salles TA, Dariolli R, Antunes F, Feitosa VA, Hunger A, Catani JPP, Mendonça SA, Tamura RE, Lana MG, Rodrigues EG, Strauss BE. Potentiation of combined p19Arf and interferon-beta cancer gene therapy through its association with doxorubicin chemotherapy. Sci Rep 2022;12:13636. [PMID: 35948616 DOI: 10.1038/s41598-022-17775-y] [Reference Citation Analysis]
2 de los Reyes AA, Kim Y. Optimal regulation of tumour-associated neutrophils in cancer progression. R Soc open sci 2022;9:210705. [DOI: 10.1098/rsos.210705] [Reference Citation Analysis]
3 Lee J, Lee D, Kim Y. Mathematical model of STAT signalling pathways in cancer development and optimal control approaches. R Soc Open Sci 2021;8:210594. [PMID: 34631119 DOI: 10.1098/rsos.210594] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
4 Del Valle PR, Mendonça SA, Antunes F, Hunger A, Tamura RE, Zanatta DB, Strauss BE. Exploration of p53 plus interferon-beta gene transfer for the sensitization of human colorectal cancer cell lines to cell death. Cancer Biol Ther 2021;22:301-10. [PMID: 33853514 DOI: 10.1080/15384047.2021.1899784] [Reference Citation Analysis]
5 Tessarollo NG, Domingues ACM, Antunes F, Luz JCDSD, Rodrigues OA, Cerqueira OLD, Strauss BE. Nonreplicating Adenoviral Vectors: Improving Tropism and Delivery of Cancer Gene Therapy. Cancers (Basel) 2021;13:1863. [PMID: 33919679 DOI: 10.3390/cancers13081863] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
6 Cerqueira OLD, Clavijo-Salomon MA, Cardoso EC, Citrangulo Tortelli Junior T, Mendonça SA, Barbuto JAM, Strauss BE. Combined p14ARF and Interferon-β Gene Transfer to the Human Melanoma Cell Line SK-MEL-147 Promotes Oncolysis and Immune Activation. Front Immunol 2020;11:576658. [PMID: 33193370 DOI: 10.3389/fimmu.2020.576658] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
7 David TIP, Cerqueira OLD, Lana MG, Medrano RFV, Hunger A, Strauss BE. Response of human melanoma cell lines to interferon-beta gene transfer mediated by a modified adenoviral vector. Sci Rep 2020;10:17893. [PMID: 33087767 DOI: 10.1038/s41598-020-74826-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
8 Wuerdemann N, Gültekin SE, Pütz K, Wittekindt C, Huebbers CU, Sharma SJ, Eckel H, Schubotz AB, Gattenlöhner S, Büttner R, Speel EJ, Klussmann JP, Wagner S, Quaas A. PD-L1 Expression and a High Tumor Infiltrate of CD8+ Lymphocytes Predict Outcome in Patients with Oropharyngeal Squamous Cells Carcinoma. Int J Mol Sci 2020;21:E5228. [PMID: 32718057 DOI: 10.3390/ijms21155228] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
9 Da-Costa RC, Vieira IL, Hunger A, Tamura RE, Strauss BE. p19Arf sensitizes B16 melanoma cells to interferon-β delivered via mesenchymal stem cells in vitro. Braz J Med Biol Res 2020;53:e8876. [PMID: 32077463 DOI: 10.1590/1414-431X20198876] [Reference Citation Analysis]
10 Vieira IL, Tamura RE, Hunger A, Strauss BE. Distinct Roles of Direct Transduction Versus Exposure to the Tumor Secretome on Murine Endothelial Cells After Melanoma Gene Therapy with Interferon-β and p19Arf. J Interferon Cytokine Res 2019;39:246-58. [PMID: 30848981 DOI: 10.1089/jir.2018.0124] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Kim Y, Lee D, Lee J, Lee S, Lawler S. Role of tumor-associated neutrophils in regulation of tumor growth in lung cancer development: A mathematical model. PLoS One 2019;14:e0211041. [PMID: 30689655 DOI: 10.1371/journal.pone.0211041] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
12 Strauss BE, Silva GRO, de Luna Vieira I, Cerqueira OLD, Del Valle PR, Medrano RFV, Mendonça SA. Perspectives for cancer immunotherapy mediated by p19Arf plus interferon-beta gene transfer. Clinics (Sao Paulo) 2018;73:e479s. [PMID: 30208166 DOI: 10.6061/clinics/2018/e479s] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
13 Medrano RFV, Hunger A, Mendonça SA, Barbuto JAM, Strauss BE. Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy. Oncotarget 2017;8:71249-84. [PMID: 29050360 DOI: 10.18632/oncotarget.19531] [Cited by in Crossref: 78] [Cited by in F6Publishing: 83] [Article Influence: 15.6] [Reference Citation Analysis]
14 Medrano RFV, Hunger A, Catani JPP, Strauss BE. Uncovering the immunotherapeutic cycle initiated by p19Arf and interferon-β gene transfer to cancer cells: An inducer of immunogenic cell death. Oncoimmunology 2017;6:e1329072. [PMID: 28811972 DOI: 10.1080/2162402X.2017.1329072] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
15 Hunger A, Medrano RF, Strauss BE. Harnessing combined p19Arf and interferon-beta gene transfer as an inducer of immunogenic cell death and mediator of cancer immunotherapy. Cell Death Dis 2017;8:e2784. [PMID: 28492558 DOI: 10.1038/cddis.2017.201] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
16 Hunger A, Medrano RF, Zanatta DB, Del Valle PR, Merkel CA, Salles TA, Ferrari DG, Furuya TK, Bustos SO, de Freitas Saito R, Costanzi-Strauss E, Strauss BE. Reestablishment of p53/Arf and interferon-β pathways mediated by a novel adenoviral vector potentiates antiviral response and immunogenic cell death. Cell Death Discov 2017;3:17017. [PMID: 28386458 DOI: 10.1038/cddiscovery.2017.17] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
17 Catani JPP, Riechelmann RP, Adjemian S, Strauss BE. Near future of tumor immunology: Anticipating resistance mechanisms to immunotherapies, a big challenge for clinical trials. Hum Vaccin Immunother 2017;13:1109-11. [PMID: 28059608 DOI: 10.1080/21645515.2016.1269046] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]